CCEL
CRYO-CELL INTL (CCEL)
NYSE
$4.47-$0.02 (-0.45%)
Price as of Oct 23, 2026 4:10 PM EDT
  • $36.2M
    Market Cap
  • 1.13%
    1-Year Change
  • Medical Care Facilities
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 71
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Cord Blood Banking Services Market: USD 49.85 Bn Opportunity to 2031 Led by Stem Cell Advancements, Says Mordor Intelligence

The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.

02/27/2026, 9:48 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$4.28
$4.57
$4.49
1-Year Range
$2.89
$4.75
$4.49
Latest Close$4.49
Change
-$0.19 (-4.23%)
Volume6,531
Market Cap$36.2M
Shares Outstanding8.1M
P/E (TTM)-18.49
Diluted EPS (TTM)-$0.24
Enterprise Value$43.9M

Information as of 10/22/2026

Company Profile

CRYO CELL INTERNATIONAL INC
CRYO CELL INTERNATIONAL INC
https://www.cryo-cell.com
$36.2M
Market Cap
-$1.9M
Net Income
Sector: Healthcare
Industry: Medical Care Facilities
700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677
813 749 2100

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key Executives

  • David I. Portnoy
  • Mark L. Portnoy
  • Oleg Mikulinsky
  • Jill Taymans
  • Joanne Kurtzberg

Current Ownership Distribution

  • Institutions16.4M (75.23%)
  • Insiders3.5M (15.84%)
  • Mutual Funds1.9M (8.93%)
  • Other0 (0.00%)